Tomasz Grabowski

Company: JJP Biologics

Job title: Head of Preclinical Development

Seminars:

Modeling Melanoma Resistance: Using Tumour Models to Validate JJP-1008 mAb Targeting CD160 & CD272 12:45 pm

Identifying CD160 and CD272 as key contributors to melanoma resistance in preclinical models, highlighting their clinical relevance in tumour immune evasion Demonstrating JJP-1008 as the first selective CD270 inhibitory signal-blocking IgG4 mAb, showing promising potential in overcoming melanoma resistance in model systems Showing through preclinical studies that JJP-1008 induces the shedding of LIGHT (CD258), offering…Read more

day: Conference Day One

Roundtable: Are GEMMs Worth the Investment? Evaluating Their Value in Cancer Research 2:00 pm

Evaluating whether the significant financial and logistical investment in GEMMs yields reliable, actionable insights that justify their use in drug discovery Investigating the gap between GEMM preclinical results and clinical trial outcomes, questioning their true predictive capacity for human patient responses Discussing the evolving role of GEMMs in precision oncology, exploring their potential to refine…Read more

day: Conference Day Two